Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

A Flow Cytometry-Based Approach to Unravel Viral Interference with the MHC Class I Antigen Processing and Presentation Pathway.

Praest P, de Buhr H, Wiertz EJHJ.

Methods Mol Biol. 2019;1988:187-198. doi: 10.1007/978-1-4939-9450-2_14.

PMID:
31147941
2.

A Genome-Wide Haploid Genetic Screen Identifies Heparan Sulfate-Associated Genes and the Macropinocytosis Modulator TMED10 as Factors Supporting Vaccinia Virus Infection.

Luteijn RD, van Diemen F, Blomen VA, Boer IGJ, Manikam Sadasivam S, van Kuppevelt TH, Drexler I, Brummelkamp TR, Lebbink RJ, Wiertz EJ.

J Virol. 2019 Jun 14;93(13). pii: e02160-18. doi: 10.1128/JVI.02160-18. Print 2019 Jul 1.

PMID:
30996093
3.

Transmembrane regions of bovine herpesvirus 1-encoded UL49.5 and glycoprotein M regulate complex maturation and ER-Golgi trafficking.

Graul M, Kisielnicka E, Rychłowski M, Verweij MC, Tobler K, Ackermann M, Wiertz EJHJ, Bieńkowska-Szewczyk K, Lipińska AD.

J Gen Virol. 2019 Mar;100(3):497-510. doi: 10.1099/jgv.0.001224. Epub 2019 Jan 29.

PMID:
30694168
4.

RNA accessibility impacts potency of Tough Decoy microRNA inhibitors.

Hooykaas MJG, Soppe JA, De Buhr HM, Kruse E, Wiertz EJHJ, Lebbink RJ.

RNA Biol. 2018;15(11):1410-1419. doi: 10.1080/15476286.2018.1537746. Epub 2018 Nov 7.

5.

The influence of TAP1 and TAP2 gene polymorphisms on TAP function and its inhibition by viral immune evasion proteins.

Praest P, Luteijn RD, Brak-Boer IGJ, Lanfermeijer J, Hoelen H, Ijgosse L, Costa AI, Gorham RD Jr, Lebbink RJ, Wiertz EJHJ.

Mol Immunol. 2018 Sep;101:55-64. doi: 10.1016/j.molimm.2018.05.025. Epub 2018 Jun 4.

6.

Mutagenic repair of double-stranded DNA breaks in vaccinia virus genomes requires cellular DNA ligase IV activity in the cytosol.

Luteijn RD, Drexler I, Smith GL, Lebbink RJ, Wiertz EJHJ.

J Gen Virol. 2018 Jun;99(6):790-804. doi: 10.1099/jgv.0.001034. Epub 2018 Apr 20.

PMID:
29676720
7.

New insights into the structure of the MHC class I peptide-loading complex and mechanisms of TAP inhibition by viral immune evasion proteins.

Praest P, Liaci AM, Förster F, Wiertz EJHJ.

Mol Immunol. 2019 Sep;113:103-114. doi: 10.1016/j.molimm.2018.03.020. Epub 2018 Mar 30.

PMID:
29606337
8.

Endocytosed soluble cowpox virus protein CPXV012 inhibits antigen cross-presentation in human monocyte-derived dendritic cells.

Spel L, Luteijn RD, Drijfhout JW, Nierkens S, Boes M, Wiertz EJH.

Immunol Cell Biol. 2018 Feb;96(2):137-148. doi: 10.1111/imcb.1024. Epub 2018 Feb 1.

PMID:
29363167
9.

Multiple E2 ubiquitin-conjugating enzymes regulate human cytomegalovirus US2-mediated immunoreceptor downregulation.

van de Weijer ML, Schuren ABC, van den Boomen DJH, Mulder A, Claas FHJ, Lehner PJ, Lebbink RJ, Wiertz EJHJ.

J Cell Sci. 2017 Sep 1;130(17):2883-2892. doi: 10.1242/jcs.206839. Epub 2017 Jul 25.

10.

EBV MicroRNA BART16 Suppresses Type I IFN Signaling.

Hooykaas MJG, van Gent M, Soppe JA, Kruse E, Boer IGJ, van Leenen D, Groot Koerkamp MJA, Holstege FCP, Ressing ME, Wiertz EJHJ, Lebbink RJ.

J Immunol. 2017 May 15;198(10):4062-4073. doi: 10.4049/jimmunol.1501605. Epub 2017 Apr 17.

11.

A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape.

Lebbink RJ, de Jong DC, Wolters F, Kruse EM, van Ham PM, Wiertz EJ, Nijhuis M.

Sci Rep. 2017 Feb 8;7:41968. doi: 10.1038/srep41968.

12.

The E3 Ubiquitin Ligase TMEM129 Is a Tri-Spanning Transmembrane Protein.

van de Weijer ML, van Muijlwijk GH, Visser LJ, Costa AI, Wiertz EJ, Lebbink RJ.

Viruses. 2016 Nov 15;8(11). pii: E309.

13.

Comprehensive profiling of functional Epstein-Barr virus miRNA expression in human cell lines.

Hooykaas MJ, Kruse E, Wiertz EJ, Lebbink RJ.

BMC Genomics. 2016 Aug 17;17:644. doi: 10.1186/s12864-016-2978-6.

14.

CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections.

van Diemen FR, Kruse EM, Hooykaas MJ, Bruggeling CE, Schürch AC, van Ham PM, Imhof SM, Nijhuis M, Wiertz EJ, Lebbink RJ.

PLoS Pathog. 2016 Jun 30;12(6):e1005701. doi: 10.1371/journal.ppat.1005701. eCollection 2016 Jun.

15.

The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells.

Gram AM, Oosenbrug T, Lindenbergh MF, Büll C, Comvalius A, Dickson KJ, Wiegant J, Vrolijk H, Lebbink RJ, Wolterbeek R, Adema GJ, Griffioen M, Heemskerk MH, Tscharke DC, Hutt-Fletcher LM, Wiertz EJ, Hoeben RC, Ressing ME.

PLoS Pathog. 2016 Apr 14;12(4):e1005550. doi: 10.1371/journal.ppat.1005550. eCollection 2016 Apr.

16.

Recent advances in viral evasion of the MHC Class I processing pathway.

Schuren AB, Costa AI, Wiertz EJ.

Curr Opin Immunol. 2016 Jun;40:43-50. doi: 10.1016/j.coi.2016.02.007. Epub 2016 Apr 8. Review.

PMID:
27065088
17.

Erratum: Exploiting the exploiter: a viral inhibitor stabilizes TAP for cryo-EM.

Luteijn RD, Wiertz EJ.

Nat Struct Mol Biol. 2016 Apr;23(4):358. doi: 10.1038/nsmb0416-358b. No abstract available.

PMID:
27045447
18.

Exploiting the exploiter: a viral inhibitor stabilizes TAP for cryo-EM.

Luteijn RD, Wiertz EJ.

Nat Struct Mol Biol. 2016 Feb;23(2):95-7. doi: 10.1038/nsmb.3168. No abstract available. Erratum in: Nat Struct Mol Biol. 2016 Apr;23(4):358.

PMID:
26840895
19.

Immune Evasion by Epstein-Barr Virus.

Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ.

Curr Top Microbiol Immunol. 2015;391:355-81. doi: 10.1007/978-3-319-22834-1_12. Review.

PMID:
26428381
20.

Suppression of a Natural Killer Cell Response by Simian Immunodeficiency Virus Peptides.

Schafer JL, Ries M, Guha N, Connole M, Colantonio AD, Wiertz EJ, Wilson NA, Kaur A, Evans DT.

PLoS Pathog. 2015 Sep 2;11(9):e1005145. doi: 10.1371/journal.ppat.1005145. eCollection 2015 Sep.

21.

Pathogenicity of Bovine Neonatal Pancytopenia-associated vaccine-induced alloantibodies correlates with Major Histocompatibility Complex class I expression.

Benedictus L, Luteijn RD, Otten H, Lebbink RJ, van Kooten PJ, Wiertz EJ, Rutten VP, Koets AP.

Sci Rep. 2015 Aug 3;5:12748. doi: 10.1038/srep12748.

22.

Proteasomal Degradation of Proinsulin Requires Derlin-2, HRD1 and p97.

Hoelen H, Zaldumbide A, van Leeuwen WF, Torfs EC, Engelse MA, Hassan C, Lebbink RJ, de Koning EJ, Resssing ME, de Ru AH, van Veelen PA, Hoeben RC, Roep BO, Wiertz EJ.

PLoS One. 2015 Jun 24;10(6):e0128206. doi: 10.1371/journal.pone.0128206. eCollection 2015.

23.

Viral immune evasion: Lessons in MHC class I antigen presentation.

van de Weijer ML, Luteijn RD, Wiertz EJ.

Semin Immunol. 2015 Mar;27(2):125-37. doi: 10.1016/j.smim.2015.03.010. Epub 2015 Apr 15. Review.

PMID:
25887630
24.

Viral inhibition of the transporter associated with antigen processing (TAP): a striking example of functional convergent evolution.

Verweij MC, Horst D, Griffin BD, Luteijn RD, Davison AJ, Ressing ME, Wiertz EJ.

PLoS Pathog. 2015 Apr 16;11(4):e1004743. doi: 10.1371/journal.ppat.1004743. eCollection 2015 Apr. Review.

25.

Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion.

van Gent M, Gram AM, Boer IG, Geerdink RJ, Lindenbergh MF, Lebbink RJ, Wiertz EJ, Ressing ME.

J Gen Virol. 2015 Apr;96(Pt 4):858-65. doi: 10.1099/jgv.0.000021. Epub 2014 Dec 12.

PMID:
25502648
26.

Cowpox virus protein CPXV012 eludes CTLs by blocking ATP binding to TAP.

Luteijn RD, Hoelen H, Kruse E, van Leeuwen WF, Grootens J, Horst D, Koorengevel M, Drijfhout JW, Kremmer E, Früh K, Neefjes JJ, Killian A, Lebbink RJ, Ressing ME, Wiertz EJ.

J Immunol. 2014 Aug 15;193(4):1578-89. doi: 10.4049/jimmunol.1400964. Epub 2014 Jul 14.

27.

A high-coverage shRNA screen identifies TMEM129 as an E3 ligase involved in ER-associated protein degradation.

van de Weijer ML, Bassik MC, Luteijn RD, Voorburg CM, Lohuis MA, Kremmer E, Hoeben RC, LeProust EM, Chen S, Hoelen H, Ressing ME, Patena W, Weissman JS, McManus MT, Wiertz EJ, Lebbink RJ.

Nat Commun. 2014 May 8;5:3832. doi: 10.1038/ncomms4832.

28.

Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with toll-like receptor signaling.

van Gent M, Braem SG, de Jong A, Delagic N, Peeters JG, Boer IG, Moynagh PN, Kremmer E, Wiertz EJ, Ovaa H, Griffin BD, Ressing ME.

PLoS Pathog. 2014 Feb 20;10(2):e1003960. doi: 10.1371/journal.ppat.1003960. eCollection 2014 Feb.

29.

TAP mediates import of Mycobacterium tuberculosis-derived peptides into phagosomes and facilitates loading onto HLA-I.

Harriff MJ, Burgdorf S, Kurts C, Wiertz EJ, Lewinsohn DA, Lewinsohn DM.

PLoS One. 2013 Nov 11;8(11):e79571. doi: 10.1371/journal.pone.0079571. eCollection 2013.

30.

MHC class I molecules are preferentially ubiquitinated on endoplasmic reticulum luminal residues during HRD1 ubiquitin E3 ligase-mediated dislocation.

Burr ML, van den Boomen DJ, Bye H, Antrobus R, Wiertz EJ, Lehner PJ.

Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14290-5. doi: 10.1073/pnas.1303380110. Epub 2013 Aug 8.

31.

The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics.

Tan L, Coenjaerts FE, Houspie L, Viveen MC, van Bleek GM, Wiertz EJ, Martin DP, Lemey P.

J Virol. 2013 Jul;87(14):8213-26. doi: 10.1128/JVI.03278-12. Epub 2013 May 22.

32.

Genetically engineered human islets protected from CD8-mediated autoimmune destruction in vivo.

Zaldumbide A, Alkemade G, Carlotti F, Nikolic T, Abreu JR, Engelse MA, Skowera A, de Koning EJ, Peakman M, Roep BO, Hoeben RC, Wiertz EJ.

Mol Ther. 2013 Aug;21(8):1592-601. doi: 10.1038/mt.2013.105. Epub 2013 May 21.

33.

Evaluation of viral interference with MHC class I-restricted antigen processing and presentation using a flow cytometry-based approach.

Horst D, Ressing ME, Mulder A, Wiertz EJHJ.

Methods Mol Biol. 2013;960:127-136. doi: 10.1007/978-1-62703-218-6_10.

PMID:
23329483
34.

Viral interference with antigen presentation: trapping TAP.

Ressing ME, Luteijn RD, Horst D, Wiertz EJ.

Mol Immunol. 2013 Sep;55(2):139-42. doi: 10.1016/j.molimm.2012.10.009. Epub 2012 Nov 8. Review.

PMID:
23141382
35.

Adenoviral vectors stimulate glucagon transcription in human mesenchymal stem cells expressing pancreatic transcription factors.

Zaldumbide A, Carlotti F, Gonçalves MA, Knaän-Shanzer S, Cramer SJ, Roep BO, Wiertz EJ, Hoeben RC.

PLoS One. 2012;7(10):e48093. doi: 10.1371/journal.pone.0048093. Epub 2012 Oct 26.

36.

Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.

Kremer AN, van der Meijden ED, Honders MW, Goeman JJ, Wiertz EJ, Falkenburg JH, Griffioen M.

Blood. 2012 Oct 18;120(16):3246-55. doi: 10.1182/blood-2011-12-399311. Epub 2012 Aug 13.

PMID:
22889757
37.

The "Bridge" in the Epstein-Barr virus alkaline exonuclease protein BGLF5 contributes to shutoff activity during productive infection.

Horst D, Burmeister WP, Boer IG, van Leeuwen D, Buisson M, Gorbalenya AE, Wiertz EJ, Ressing ME.

J Virol. 2012 Sep;86(17):9175-87. doi: 10.1128/JVI.00309-12. Epub 2012 Jun 13.

38.

Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation.

Horst D, Burrows SR, Gatherer D, van Wilgenburg B, Bell MJ, Boer IG, Ressing ME, Wiertz EJ.

J Virol. 2012 Jan;86(1):572-7. doi: 10.1128/JVI.05151-11. Epub 2011 Oct 19.

39.

Structural and functional analysis of the TAP-inhibiting UL49.5 proteins of varicelloviruses.

Verweij MC, Lipińska AD, Koppers-Lalic D, Quinten E, Funke J, van Leeuwen HC, Bieńkowska-Szewczyk K, Koch J, Ressing ME, Wiertz EJ.

Mol Immunol. 2011 Sep;48(15-16):2038-51. doi: 10.1016/j.molimm.2011.06.438. Epub 2011 Jul 20.

PMID:
21764135
40.

Exploiting human herpesvirus immune evasion for therapeutic gain: potential and pitfalls.

Horst D, Ressing ME, Wiertz EJ.

Immunol Cell Biol. 2011 Mar;89(3):359-66. doi: 10.1038/icb.2010.129. Epub 2011 Feb 8. Review.

PMID:
21301483
41.

EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP.

Horst D, Favaloro V, Vilardi F, van Leeuwen HC, Garstka MA, Hislop AD, Rabu C, Kremmer E, Rickinson AB, High S, Dobberstein B, Ressing ME, Wiertz EJ.

J Immunol. 2011 Mar 15;186(6):3594-605. doi: 10.4049/jimmunol.1002656. Epub 2011 Feb 4.

42.

Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses.

Verweij MC, Ressing ME, Knetsch W, Quinten E, Halenius A, van Bel N, Hengel H, Drijfhout JW, van Hall T, Wiertz EJ.

Mol Immunol. 2011 Mar;48(6-7):835-45. doi: 10.1016/j.molimm.2010.12.008. Epub 2011 Feb 2.

43.

Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of human mesenchymal stem cell transplants.

de la Garza-Rodea AS, Verweij MC, Boersma H, van der Velde-van Dijke I, de Vries AA, Hoeben RC, van Bekkum DW, Wiertz EJ, Knaän-Shanzer S.

PLoS One. 2011 Jan 6;6(1):e14493. doi: 10.1371/journal.pone.0014493.

44.

EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection.

van Gent M, Griffin BD, Berkhoff EG, van Leeuwen D, Boer IG, Buisson M, Hartgers FC, Burmeister WP, Wiertz EJ, Ressing ME.

J Immunol. 2011 Feb 1;186(3):1694-702. doi: 10.4049/jimmunol.0903120. Epub 2010 Dec 29.

45.

The capacity of UL49.5 proteins to inhibit TAP is widely distributed among members of the genus Varicellovirus.

Verweij MC, Lipinska AD, Koppers-Lalic D, van Leeuwen WF, Cohen JI, Kinchington PR, Messaoudi I, Bienkowska-Szewczyk K, Ressing ME, Rijsewijk FA, Wiertz EJ.

J Virol. 2011 Mar;85(5):2351-63. doi: 10.1128/JVI.01621-10. Epub 2010 Dec 15.

46.

Viral evasion of T cell immunity: ancient mechanisms offering new applications.

Horst D, Verweij MC, Davison AJ, Ressing ME, Wiertz EJ.

Curr Opin Immunol. 2011 Feb;23(1):96-103. doi: 10.1016/j.coi.2010.11.005. Epub 2010 Dec 9. Review.

47.

Noncytotoxic inhibition of cytomegalovirus replication through NK cell protease granzyme M-mediated cleavage of viral phosphoprotein 71.

van Domselaar R, Philippen LE, Quadir R, Wiertz EJ, Kummer JA, Bovenschen N.

J Immunol. 2010 Dec 15;185(12):7605-13. doi: 10.4049/jimmunol.1001503. Epub 2010 Nov 8.

48.

CD8+ T cell responses against TAP-inhibited cells are readily detected in the human population.

Lampen MH, Verweij MC, Querido B, van der Burg SH, Wiertz EJ, van Hall T.

J Immunol. 2010 Dec 1;185(11):6508-17. doi: 10.4049/jimmunol.1001774. Epub 2010 Oct 27.

49.

Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.

van Luijn MM, Chamuleau ME, Ressing ME, Wiertz EJ, Ostrand-Rosenberg S, Souwer Y, Zevenbergen A, Ossenkoppele GJ, van de Loosdrecht AA, van Ham SM.

Cancer Immunol Immunother. 2010 Dec;59(12):1825-38. doi: 10.1007/s00262-010-0908-z. Epub 2010 Sep 5.

50.

Herpesviruses and immunity: the art of evasion.

Griffin BD, Verweij MC, Wiertz EJ.

Vet Microbiol. 2010 Jun 16;143(1):89-100. doi: 10.1016/j.vetmic.2010.02.017. Epub 2010 Feb 25. Review.

PMID:
20303681

Supplemental Content

Loading ...
Support Center